You are now leaving XTANDI.com
The website you are about to visit is not owned or controlled by Astellas. Astellas are not responsible for the information or services on this site.
In May 2017, Astellas acquired Ogeda, a clinical-stage drug discovery company. Located in Gosselies, Belgium, Ogeda focuses on discovering and developing small molecule drugs targeting G-protein coupled receptors (GPCRs).
The addition of Ogeda's lead investigational candidate, fezolinetant, a small-molecule selective neurokinin-3 (NK3) receptor antagonist, is an important asset that advances our late-stage clinical pipeline. We are investigating fezolinetant as a potential non-hormonal oral therapy for menopause-related vasomotor symptoms (MR-VMS), or “hot flashes,” which are commonly experienced during menopause.
"This acquisition helps us focus on advancing our scientific research to deliver value and innovative treatments to patients in therapeutic areas with high unmet medical needs," said Arwin Ridder, global development project leader, Therapeutic Area Urology & Nephrology. "Ultimately, we want to deliver a potential new treatment option to patients suffering from MR-VMS.”
What is VMS?
VMS represents a bothersome symptom of menopause – hot flashes. It is associated with a sudden sensation of heat in the face, neck and chest and persists for several minutes or fewer. It may take 30 minutes or longer for the skin temperature to return to baseline. These symptoms can disturb sleep and compromise working time. VMS impacts a high proportion of women. It is projected that more than 500 million women (50 million U.S. women) in 2020 will be older than 51 – many of them troubled by years of VMS.
[1] https://www.census.gov/population/international/data/idb/worldpop.php
Get only the email alerts you want.
For media inquiries and reporter requests, please click here to fill out a request form.
Our communications team will respond to verified media requests within 24-48 hours as appropriate.
If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
The site uses cookies to provide you with a more responsive and personalized service and to analyze site traffic. By using this site, you accept our use of cookies as described in our privacy policy. Please read our privacy policy for more information on the cookies we use, the processing of your personal data and how to delete or block the use of cookies.